The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial
Open accessAbstract
Background Surgical resection of early stage hepatocellular carcinoma is standard clinical practice; however, most tumours recur despite surgery, and no perioperative intervention has shown a survival benefit. Neoadjuvant immunotherapy has induced pathological responses in multiple tumour types and might decrease the risk of postoperative recurrence in hepatocellular carcinoma. We aimed to evaluate the clinical activity of neoadjuvant cemiplimab (an anti-PD-1) in patients with resectable hepatocellular carcinoma.Methods For this single-arm, open-label, phase 2 trial, patients with resectable hepatocellular carcinoma (stage Ib, II, and IIIb) were enrolled and received two cycles of neoadjuvant cemiplimab 350 mg intravenously every 3 weeks followed by surgical resection. Eligible patients were aged 18 years or older, had confirmed resectable hepatocellular carcinoma, an Eastern Cooperative Oncology Group performance status of 0 or 1, and adequate liver function. Patients were excluded if they had metastatic disease, if the surgery was not expected to be curative, if they had a known additional malignancy requiring active treatment, or if they required systemic steroid treatment or any other immunosuppressive therapy. After resection, patients received an additional eight cycles of cemiplimab 350 mg intravenously every 3 weeks in the adjuvant setting. The primary endpoint was significant tumour necrosis on pathological examination (defined as >70% necrosis of the resected tumour). Secondary endpoints included delay of surgery, the proportion of patients with an overall response, change in CD8+ T-cell density, and adverse events. Tumour necrosis and response were analysed in all patients who received at least one dose of cemiplimab and completed surgical resection; safety and other endpoints were analysed in the intention-to-treat population. Patients underwent pre-treatment biopsies and blood collection throughout treatment. This trial is registered with ClinicalTrials.gov (NCT03916627, Cohort B) and is ongoing.Findings Between Aug 5, 2019, and Nov 25, 2020, 21 patients were enrolled. All patients received neoadjuvant cemiplimab, and 20 patients underwent successful resection. Of the 20 patients with resected tumours, four (20%) had significant tumour necrosis. Three (15%) of 20 patients had a partial response, and all other patients maintained stable disease. 20 (95%) patients had a treatment-emergent adverse event of any grade during the neoadjuvant treatment period. The most common adverse events of any grade were increased aspartate aminotransferase (in four patients), increased blood creatine phosphokinase (in three), constipation (in three), and fatigue (in three). Seven patients had grade 3 adverse events, including increased blood creatine phosphokinase (in two patients) and hypoalbuminaemia (in one). No grade 4 or 5 events were observed. One patient developed pneumonitis, which led to a delay in surgery by 2 weeks.Interpretation This report is, to our knowledge, the largest clinical trial of a neoadjuvant anti-PD-1 monotherapy reported to date in hepatocellular carcinoma. The observed pathological responses to cemiplimab in this cohort support the design of larger trials to identify the optimal treatment duration and definitively establish the clinical benefit of preoperative PD-1 blockade in patients with hepatocellular carcinoma.Funding Regeneron Pharmaceuticals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Preoperative use of ICIs in patients with hepatocellular carcinoma has been explored in several small, early-phase studies, in which heterogeneous therapeutic combinations were tested, mainly with safety and feasibility being the primary endpoints assessed.7–12”
From Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis (2024) · cites this paper as [7]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“profound pathological responses can occur as little as 22 days before surgery13”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a phase II clinical trial with results published in 2022, patients with early stage HCC received neoadjuvant treatment with the anti-PD-1 antibody cemiplimab13. Significant tumour necrosis, the prespecified primary end point, was 20%.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The estimated duration of neoadjuvant approaches — aimed to achieve a balance between exposure to ICIs and prevention of tumour progression — is estimated to be around 6–8 weeks, but longer time frames might be justified based on clinical activity of a regimen13,15.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, none of these studies were individually powered to robustly investigate predictive factors of efficacy from neoadjuvant ICI therapy, particularly with regards to long-term survival outcomes, including relapse-free survival.”
From Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis (2024) · cites this paper as [7]
Experimental — accuracy not yet measured
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Finn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01307 · Cited by 1,789
CD8+ T cell states in human cancer: insights from single-cell analysis
van der Leun, A. M., Thommen, D. S., & Schumacher, T. N. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0235-4 · Cited by 1,472
Chalabi, M., Fanchi, L. F., Dijkstra, K. K., Van den Berg, J. G., Aalbers, A. G., Sikorska, K., Lopez-Yurda, M., Grootscholten, C., Beets, G. L., Snaebjornsson, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0805-8 · Cited by 1,417
Cited by
Vogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Qin, S., Chen, M., Cheng, A.-L., Kaseb, A. O., Kudo, M., Lee, H. C., Yopp, A. C., Zhou, J., Wang, L., Wen, X., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01796-8 · Cited by 545
Magen, A., Hamon, P., Fiaschi, N., Soong, B. Y., Park, M. D., Mattiuz, R., Humblin, E., Troncoso, L., D’souza, D., Dawson, T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02345-0 · Cited by 429
Self-citationAdjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
Self-citation
Metadata
- Authors
- Marron, T. U., Fiel, M. I., Hamon, P., Fiaschi, N., Kim, E., Ward, S. C., Zhao, Z., Kim, J., Kennedy, P., Gunasekaran, G., Tabrizian, P., Doroshow, D., Legg, M., Hammad, A., Magen, A., Kamphorst, A. O., Shareef, M., Gupta, N. T., Deering, R., Wang, W., Wang, F., Thanigaimani, P., Mani, J., Troncoso, L., Tabachnikova, A., Chang, C., Akturk, G., Buckup, M., Hamel, S., Ioannou, G., Hennequin, C., Jamal, H., Brown, H., Bonaccorso, A., Labow, D., Sarpel, U., Rosenbloom, T., Sung, M. W., Kou, B., Li, S., Jankovic, V., James, N., Hamon, S. C., Cheung, H. K., Sims, J. S., Miller, E., Bhardwaj, N., Thurston, G., Lowy, I., Gnjatic, S., Taouli, B., Schwartz, M. E., & Merad, M.
- Affiliations
- Tisch Cancer Institute (US)
- Icahn School of Medicine at Mount Sinai (US)
- Regeneron (United States) (US)
- Mount Sinai Health System (US)
- Corresponding author
- Marron, Thomas U
- ORCID
- Marron, Thomas U
- Fiel, Maria Isabel
- Hamon, Pauline
- Fiaschi, Nathalie
- Kim, Edward
- Ward, Stephen C
- Zhao, Zhen
- Kennedy, Paul
- Gunasekaran, Ganesh
- Tabrizian, Parissa
- Doroshow, Deborah
- Magen, Assaf
- Kamphorst, Alice O
- Shareef, Muhammed
- Gupta, Namita T
- Deering, Raquel
- Wang, Wei
- Wang, Fang
- Mani, Jayakumar
- Troncoso, Leanna
- Tabachnikova, Alexandra
- Chang, Christie
- Buckup, Mark
- Hamel, Steven
- Ioannou, Giorgio
- Sarpel, Umut
- Sung, Max W
- Li, Siyu
- James, Nicola
- Hamon, Sara C
- Bhardwaj, Nina
- Thurston, Gavin
- Lowy, Israel
- Gnjatic, Sacha
- Taouli, Bachir
- Schwartz, Myron E
- Venue
- The Lancet Gastroenterology & Hepatology
- Publisher
- Elsevier BV
- Published
- 2022-03
- Volume
- 7
- Issue
- 3
- Pages
- 219-229
- ISSN
- 2468-1156 (ISSN-L)
- 2468-1253
- PMC
- PMC9901534
- OpenAlex
- W4206656883
- Cited by
- 239
- References
- 30
- Citations by year
- 2026: 40 · 2025: 65 · 2024: 65 · 2023: 47 · 2022: 21
- FWCI
- 29.45
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet. Gastroenterology & hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- cemiplimab, neoadjuvant immunotherapy, hepatocellular carcinoma, resectable liver cancer, anti-PD-1 therapy, surgical resection, adjuvant immunotherapy, tumor necrosis, postoperative recurrence, immune-related adverse events, overall survival, progression-free survival, prognostic factors
- MeSH terms
- Antineoplastic Agents, Immunological, Aged, Aged, 80 and over, Aspartate Aminotransferases, Creatine Kinase, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Neoadjuvant Therapy, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. https://app.cochat.ai/papers/10.1016/s2468-1253(21)00385-x
- The paper
- Marron, T. U., Fiel, M. I., Hamon, P., Fiaschi, N., Kim, E., Ward, S. C., Zhao, Z., Kim, J., Kennedy, P., Gunasekaran, G., Tabrizian, P., Doroshow, D., Legg, M., Hammad, A., Magen, A., Kamphorst, A. O., Shareef, M., Gupta, N. T., Deering, R., . . . Merad, M. (2022). Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(21)00385-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.